Robert Janssen - 16 Nov 2021 Form 4 Insider Report for DYNAVAX TECHNOLOGIES CORP (DVAX)

Role: Senior Vice President
Signature: /s/ Robert Janssen
Issuer symbol: DVAX
Transactions as of: 16 Nov 2021
Net transactions value: -$593,701
Form type: 4
Filing time: 18 Nov 2021, 16:06:59 UTC
Previous filing: 03 Sep 2021
Next filing: 14 Feb 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	DVAX	Common Stock	Options Exercise	$376,648	+35,974	+435%	$10.47	44,250	16 Nov 2021	Direct
transaction	DVAX	Common Stock	Sale	$617,479	-35,974	-81%	$17.16	8,276	16 Nov 2021	Direct	F1
transaction	DVAX	Common Stock	Options Exercise	$559,423	+53,431	+646%	$10.47	61,707	17 Nov 2021	Direct
transaction	DVAX	Common Stock	Sale	$912,292	-53,431	-87%	$17.07	8,276	17 Nov 2021	Direct	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	DVAX	Stock Option (Right to Buy)	Options Exercise		-35,974	-35%		67,126	16 Nov 2021	Common Stock	35,974	$10.47	Direct	F3, F4
transaction	DVAX	Stock Option (Right to Buy)	Options Exercise		-53,431	-80%		13,695	17 Nov 2021	Common Stock	53,431	$10.47	Direct	F3, F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	This transaction was executed in multiple trades at prices ranging from $17.01 to $17.27; the price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and prices at which the transactions were effected upon request to the SEC staff, Dynavax, or a security holder of Dynavax.
F2	This transaction was executed in multiple trades at prices ranging from $16.92 to $17.30; the price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and prices at which the transactions were effected upon request to the SEC staff, Dynavax, or a security holder of Dynavax.
F3	This option grant will vest over three (3) years with one-third (1/3) of the shares subject to the option vesting twelve months after the grant date, and one thirty-sixth (1/36) of the shares subject to the option vesting on the last day of each month thereafter.
F4	Not applicable